GR1005808B - Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων - Google Patents

Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Info

Publication number
GR1005808B
GR1005808B GR20060100644A GR20060100644A GR1005808B GR 1005808 B GR1005808 B GR 1005808B GR 20060100644 A GR20060100644 A GR 20060100644A GR 20060100644 A GR20060100644 A GR 20060100644A GR 1005808 B GR1005808 B GR 1005808B
Authority
GR
Greece
Prior art keywords
erythropoietin
receptor agonists
potentiation
epo
action
Prior art date
Application number
GR20060100644A
Other languages
English (en)
Inventor
-
Original Assignee
Bionature E.A. Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionature E.A. Limited filed Critical Bionature E.A. Limited
Priority to GR20060100644A priority Critical patent/GR1005808B/el
Priority to EP07824728A priority patent/EP2099473A2/en
Priority to US12/516,340 priority patent/US20100086542A1/en
Priority to AU2007327099A priority patent/AU2007327099A1/en
Priority to CA002670955A priority patent/CA2670955A1/en
Priority to JP2009538777A priority patent/JP2010511026A/ja
Priority to PCT/GB2007/004537 priority patent/WO2008065387A2/en
Publication of GR1005808B publication Critical patent/GR1005808B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αξιώνει την σύγχρονη χρήση ενεργοποιητών των μεμβρανικών υποδοχέων στεροιεδών και ερυθροποιητίνης με σκοπό τον έλεγχο του παλλαπλασιασμού,της διαφοροποιήσεως, και της μεταναστευτικής και αναγεννητικής ικανότητος κυττάρων, ιστών ή οργάνων.
GR20060100644A 2006-11-27 2006-11-27 Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων GR1005808B (el)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GR20060100644A GR1005808B (el) 2006-11-27 2006-11-27 Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων
EP07824728A EP2099473A2 (en) 2006-11-27 2007-11-27 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists
US12/516,340 US20100086542A1 (en) 2006-11-27 2007-11-27 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists
AU2007327099A AU2007327099A1 (en) 2006-11-27 2007-11-27 Potentiation of erythropoietin (EPO) action by membrane steroid receptor agonists
CA002670955A CA2670955A1 (en) 2006-11-27 2007-11-27 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists
JP2009538777A JP2010511026A (ja) 2006-11-27 2007-11-27 膜ステロイド受容体アゴニストによるエリスロポエチン（ｅｐｏ）作用の増強
PCT/GB2007/004537 WO2008065387A2 (en) 2006-11-27 2007-11-27 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20060100644A GR1005808B (el) 2006-11-27 2006-11-27 Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Publications (1)

Publication Number Publication Date
GR1005808B true GR1005808B (el) 2008-02-06

Family

ID=39205096

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20060100644A GR1005808B (el) 2006-11-27 2006-11-27 Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Country Status (7)

Country Link
US (1) US20100086542A1 (el)
EP (1) EP2099473A2 (el)
JP (1) JP2010511026A (el)
AU (1) AU2007327099A1 (el)
CA (1) CA2670955A1 (el)
GR (1) GR1005808B (el)
WO (1) WO2008065387A2 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962364B2 (en) 2012-12-26 2018-05-08 A-Z Ltd. Wound healing accelerator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1423693A4 (en) * 2001-08-02 2006-06-07 Ortho Mcneil Pharm Inc COMBINATION THERAPY WITH ERYTHROPOETIN AND ANTI-TUMORNEKROSE FACTOR ALPHA
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions

Also Published As

Publication number Publication date
CA2670955A1 (en) 2008-06-05
EP2099473A2 (en) 2009-09-16
WO2008065387A3 (en) 2008-07-31
JP2010511026A (ja) 2010-04-08
WO2008065387A2 (en) 2008-06-05
AU2007327099A1 (en) 2008-06-05
US20100086542A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
AU2015213344B2 (en) Novel CC-1065 analogs and their conjugates
MY159971A (en) Multipotent/pluripotent cells and methods
TW200732347A (en) VEGF analogs and methods of use
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
EP3461507A8 (en) Cell-scaffold constructs
PH12015500093A1 (en) Il-17 binding proteins
MX2011006574A (es) Agonistas del receptor gpr120 y usos de los mismos.
SG158133A1 (en) Method for reversing multiple resistance in animal cells
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EA201101519A1 (ru) Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP3539380A3 (en) Improved cell composition and methods of making the same
FR2964565B1 (fr) Composition cosmetique comprenant un polymere fixant et un agent antipelliculaire
ATE542553T1 (de) Dezellularisierte omentummatrix und ihre verwendung
EP2061907A4 (en) TCL1 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) REGULATED BY MIR-29 AND MIR-181
MX2010013876A (es) Agonistas de arilo grpr119 y sus usos .
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
HK1130009A1 (en) Fgf-peceptor agonist dimeric compounds fgf
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2007103865A3 (en) Oral tissue regeneration and repair
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
EA200800713A1 (ru) Аморфные твёрдые дисперсии
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
IN2012DN03178A (el)
GR1005808B (el) Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20120605